 RESEARCH TRIANGLE PARK, N.C., June 24, 2021 GLOBE NEWSWIRE -- Fennec Pharmaceuticals Inc. NASDAQ:FENC; TSX: FRX, a specialty pharmaceutical company focused on the development of PEDMARKTM a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors, today announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from 18 million to 20 million. 